Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.

Alimentary pharmacology & therapeutics - 1 Feb 2002

Moreno-Monteagudo J A, Castro A, De Pedro A, Lorenzo J A, Fernández-Bermejo M, Lopez S, García-Buey L, Borque M J, Pedreira J D, Moreno-Otero R

Abstract excerpt

BACKGROUND: The effectiveness and tolerability of combination therapy for 12 months have not been evaluated sufficiently in chronic hepatitis C relapsers to interferon. AIMS: To evaluate the sustained response to interferon plus ribavirin for 12 months in chronic hepatitis C relapsers. METHODS: We included 55 chronic hepatitis C relapsers in a 12-month treatment protocol with interferon (3 MU thrice weekly) plus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to gamma-Glutamyltransferase

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 11860407
DOI: 10.1046/j.1365-2036.2002.01162.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.PMID 11860407Read ↗

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.Semantic proximity Read ↗

Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.Semantic proximity Read ↗

Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?Semantic proximity Read ↗

Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.Semantic proximity Read ↗

Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.Semantic proximity Read ↗

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

[Retreatment with interferon plus ribavirin in chronic hepatitis C patients with genotype 1 who had no response or a relapse with a previous interferon treatment. Long term follow-up].Semantic proximity Read ↗

Sustained virological response after treatment in patients with chronic hepatitis C infection--a five year follow up.Semantic proximity Read ↗

Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?Semantic proximity Read ↗

How sustained is sustained viral response in patients with hepatitis C virus infection?Semantic proximity Read ↗

Identifying HCV genotype 1 patients at risk of relapse.Semantic proximity Read ↗

Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.